ISSAR Pharma

Home       Our Capabilities       Pipeline

Development Pipeline

Solving the unmet healthcare needs using novel peptide technology

ISSAR Pharmaceuticals is focused on discovery and development of peptide based New Chemical Entities (NCEs), which are best in class with anti-microbial, anti-inflammatory and anti-angiogenic properties for a wide range of disease areas such as inflammation, wound healing, infections, psoriasis, ulcerative colitis and pigmentation disorders.

Melgain®
Vitiligo - Topical

Xylentra®
Wound care - Topical

IS - 107
Solid tumors - Injectable

IS - 217
Soriacare®
Psoriasis - Injectable
Topical

ISSAR'S Pre-Clinical
Pipeline

INDIA
INDIA
INDIA
INDIA
US FDA
IBD (Injectable)
Sepsis (Injectable)
Rheumatoid Arthritis
Atopic Dermatitis

Psoriasis Drug Pipeline Analysis

Can Peptide Be a Game Changer In The Treatment Of Psoriasis?

Peptide Drug Pipeline Analysis

Peptides are going to be the new future: the current state of peptide drug discovery - Pipeline Analysis